Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/301% above fair value
$69.00−0.84 (-1.20%)
Close on Nov 13, 2026Market cap $16.84BP/E 20.7Yield –
Exelixis operating margin
Operating margin is operating income as a percentage of revenue.
Exelixis's operating margin for the twelve months ending Oct 2, 2026 was 40.2%. For fiscal 2025 it was 37.6%, against 27.9% the year before. The highest annual figure on record is 51.4% in fiscal 2018.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | 37.6% | +9.7 |
| FY2024 | Jan 3, 2025 | 27.9% | +18.5 |
| FY2023 | Dec 29, 2023 | 9.3% | −3.2 |
| FY2022 | Dec 30, 2022 | 12.5% | −7.5 |
| FY2021 | Dec 31, 2021 | 20.0% | +8.8 |
| FY2020 | Jan 1, 2021 | 11.1% | −27.0 |
| FY2019 | Jan 3, 2020 | 38.2% | −13.2 |
| FY2018 | Dec 28, 2018 | 51.4% | +14.7 |
| FY2017 | Dec 29, 2017 | 36.7% | +51.4 |
| FY2016 | Dec 31, 2016 | -14.7% | +312.0 |
| FY2015 | Dec 31, 2015 | -326.6% | +567.2 |
| FY2014 | Dec 31, 2014 | -893.9% | −253.3 |
| FY2013 | Dec 31, 2013 | -640.5% | −382.5 |
| FY2012 | Dec 31, 2012 | -258.0% | −288.9 |
| FY2011 | Dec 31, 2011 | 30.9% | +80.3 |
| FY2010 | Dec 31, 2010 | -49.4% | +30.9 |
| FY2009 | Dec 31, 2009 | -80.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | 40.8% | +1.2 |
| Q2 FY2026 | Jul 3, 2026 | 39.5% | +1.9 |
| Q1 FY2026 | Apr 3, 2026 | 41.1% | +7.5 |
| Q4 FY2025 | Jan 2, 2026 | 39.3% | +10.5 |
| Q3 FY2025 | Oct 3, 2025 | 39.6% | +14.4 |
| Q2 FY2025 | Jul 4, 2025 | 37.6% | −5.7 |
| Q1 FY2025 | Apr 4, 2025 | 33.6% | +26.7 |
| Q4 FY2024 | Jan 3, 2025 | 28.8% | +11.7 |
| Q3 FY2024 | Sep 27, 2024 | 25.2% | +28.9 |
| Q2 FY2024 | Jun 28, 2024 | 43.3% | +26.7 |
| Q1 FY2024 | Mar 29, 2024 | 6.9% | −0.1 |
| Q4 FY2023 | Dec 29, 2023 | 17.1% | +28.4 |
| Q3 FY2023 | Sep 29, 2023 | -3.7% | −23.8 |
| Q2 FY2023 | Jun 30, 2023 | 16.6% | −3.4 |
| Q1 FY2023 | Mar 31, 2023 | 7.1% | −16.3 |
| Q4 FY2022 | Dec 30, 2022 | -11.3% | −37.2 |
| Q3 FY2022 | Sep 30, 2022 | 20.1% | +4.3 |
| Q2 FY2022 | Jul 1, 2022 | 20.0% | −12.0 |
| Q1 FY2022 | Apr 1, 2022 | 23.4% | +25.1 |
| Q4 FY2021 | Dec 31, 2021 | 25.9% | +16.9 |
| Q3 FY2021 | Oct 1, 2021 | 15.7% | +34.1 |
| Q2 FY2021 | Jul 2, 2021 | 31.9% | +2.8 |
| Q1 FY2021 | Apr 2, 2021 | -1.7% | −25.0 |
| Q4 FY2020 | Jan 1, 2021 | 9.0% | −23.2 |
| Q3 FY2020 | Oct 2, 2020 | -18.4% | −61.0 |
| Q2 FY2020 | Jul 3, 2020 | 29.1% | −9.2 |
| Q1 FY2020 | Apr 3, 2020 | 23.3% | −16.0 |
| Q4 FY2019 | Jan 3, 2020 | 32.2% | −16.6 |
| Q3 FY2019 | Sep 27, 2019 | 42.5% | −13.0 |
| Q2 FY2019 | Jun 28, 2019 | 38.3% | −7.8 |
| Q1 FY2019 | Mar 29, 2019 | 39.2% | −15.2 |
| Q4 FY2018 | Dec 28, 2018 | 48.8% | +17.6 |
| Q3 FY2018 | Sep 28, 2018 | 55.5% | +2.3 |
| Q2 FY2018 | Jun 29, 2018 | 46.1% | +18.7 |
| Q1 FY2018 | Mar 30, 2018 | 54.4% | +29.5 |
| Q4 FY2017 | Dec 29, 2017 | 31.2% | −18.9 |
| Q3 FY2017 | Sep 30, 2017 | 53.2% | – |
| Q2 FY2017 | Jun 30, 2017 | 27.4% | – |
| Q1 FY2017 | Mar 31, 2017 | 25.0% | – |
| Q4 FY2016 | Dec 31, 2016 | 50.1% | – |
See a number that looks wrong?